Cargando…

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deiana, Chiara, Fabbri, Francesca, Tavolari, Simona, Palloni, Andrea, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342038/ https://www.ncbi.nlm.nih.gov/pubmed/37445594 http://dx.doi.org/10.3390/ijms241310415

Ejemplares similares

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
por: Brandi, Giovanni, et al.
Publicado: (2015)

Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
por: Tavolari, Simona, et al.
Publicado: (2023)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021)

Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
por: Brandi, Giovanni, et al.
Publicado: (2020)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

Targeting Calcium Signalling in Malignant Mesothelioma †
por: Martinotti, Simona, et al.
Publicado: (2019)

Malignant mesothelioma
por: Moore, Alastair J, et al.
Publicado: (2008)

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
por: Klampatsa, Astero, et al.
Publicado: (2020)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Oncolytic virotherapy for human malignant mesothelioma: recent advances
por: Boisgerault, Nicolas, et al.
Publicado: (2015)

Malignant mesothelioma
por: Ahmed, Ishtiaq, et al.
Publicado: (2013)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
por: Cersosimo, Francesca, et al.
Publicado: (2021)

Mesothelium and Malignant Mesothelioma
por: Hiriart, Emilye, et al.
Publicado: (2019)

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
por: Borea, Federica, et al.
Publicado: (2023)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
por: Garajová, Ingrid, et al.
Publicado: (2017)

Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach
por: Lisini, Daniela, et al.
Publicado: (2021)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Genomics and Epigenetics of Malignant Mesothelioma
por: Sage, Adam P., et al.
Publicado: (2018)

Diagnostic imaging and workup of malignant pleural mesothelioma
por: Cardinale, Luciano, et al.
Publicado: (2017)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
por: Birnie, Kimberly A., et al.
Publicado: (2017)

A Case of Advanced Malignant Pleural Mesothelioma Treatment with Chemotherapy and Photodynamic Therapy
por: Ryu, Jae-Wook, et al.
Publicado: (2015)

Clinical staging of malignant pleural mesothelioma: current perspectives
por: Bonomi, Maria, et al.
Publicado: (2017)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_iim9upaoqrqh448s94fbilb90b